Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

English

Regional settings

Entity•Capital Com UK LimitedAuthorised and regulated by the Financial Conduct Authority (FCA)

My account

Home Markets SharesGreenwich LifeSciences, Inc.

Trade Greenwich LifeSciences, Inc. - GLSI CFD

Summary Historical Data

Trading Conditions

Spread

0.67

Long position overnight fee

Long position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	-0.026179 % (-$1.05)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

-0.026179%

Short position overnight fee

Short position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	0.003957 % ($0.16)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

0.003957%

Overnight fee time

21:00 (UTC)

Currency

USD

Min traded quantity

Margin

Stock exchange

United States of America

Commission on trade¹

¹Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats

Prev. Close	12.4
Open	12.04
1-Year Change	12.1%
Day's Range	12.04 - 12.99

Greenwich LifeSciences, Inc. Company profile

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.